You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.
Johannesson M, Söderberg L, Zachrisson O, et al. (2024) Lecanemab demonstrates highly selective binding to Aβ protofibrils isolated from Alzheimer's disease brains. Molecular and Cellular Neurosciences. 130: 103949
Rizoska B, Zachrisson O, Appelkvist P, et al. (2024) Disease modifying effects of the amyloid-beta protofibril-selective antibody mAb158 in aged Tg2576 transgenic mice. Molecular and Cellular Neurosciences. 130: 103950
Söderberg L, Johannesson M, Gkanatsiou E, et al. (2024) Amyloid-beta antibody binding to cerebral amyloid angiopathy fibrils and risk for amyloid-related imaging abnormalities. Scientific Reports. 14: 10868
Pagnon de la Vega M, Syvänen S, Giedraitis V, et al. (2024) Altered amyloid-β structure markedly reduces gliosis in the brain of mice harboring the Uppsala APP deletion. Acta Neuropathologica Communications. 12: 22
Lannfelt L. (2023) A light at the end of the tunnel - from mutation identification to a potential treatment for Alzheimer's disease. Upsala Journal of Medical Sciences. 128
Hampel H, Hu Y, Hardy J, et al. (2023) The amyloid-β pathway in Alzheimer's disease: a plain language summary. Neurodegenerative Disease Management
Condello C, Maxwell AM, Castillo E, et al. (2022) Aβ and tau prions feature in the neuropathogenesis of Down syndrome. Proceedings of the National Academy of Sciences of the United States of America. 119: e2212954119
Söderberg L, Johannesson M, Nygren P, et al. (2022) Lecanemab, Aducanumab, and Gantenerumab - Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer's Disease. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics
Pagnon de la Vega M, Näslund C, Brundin R, et al. (2022) Mutation analysis of disease causing genes in patients with early onset or familial forms of Alzheimer's disease and frontotemporal dementia. Bmc Genomics. 23: 99
Rofo F, Buijs J, Falk R, et al. (2021) Novel multivalent design of a monoclonal antibody improves binding strength to soluble aggregates of amyloid beta. Translational Neurodegeneration. 10: 38